Immunohistochemical markers in the differential diagnosis of endometrial carcinomas versus endocervical adenocarcinomas
| vim | ER | PR | p53 | p16 | HNF1β | WT1 | CEA | Specific | |
| Endometrial carcinoma | |||||||||
| EMC | + | + | + | wt>M | −/+ | − | − | − | PTEN and MMR loss |
| USC | + | − | − | M | + | − | − | − | |
| CCC | + | − | − | wt>M | − | + | −/+ | − | HNF1β, Napsin A MMR loss |
| UC | − | − | − | M>wt | −/+ | − | − | − | E-cadherin and MMR loss |
| MMMT | + | −/+ | −/+ | M | + | − | +/− | − | Myogenin, S100, Myo-D1. Biphasic pattern |
| Endocervical adenocarcinoma | |||||||||
| AIS | − | −/+ | −/+ | wt | + | − | − | + | HPV+ |
| EAC, usual type | − | −/+ | −/+ | wt | + | −/+ | − | + | HPV+ |
| MC, gastric type | − | − | − | M>wt | −/+ | + | − | +/− | MUC6, HIK1083, STK11 mutation |
| MC, intestinal type | − | − | − | + | − | − | + | CDX2, HPV+ | |
| Mesonephric carcinoma | +/− | −/+ | − | wt | −/+ | −/+ | − | − | TTF1, GATA3, calretinin |
| EMC | −/+ | −/+ | −/+ | wt | −/ + | NA | − | +/− | HPV+ |
| Serous carcinoma | − | −/+ | −/+ | wt>M | + | NA | −/+ | + | HPV+ |
| Clear cell carcinoma | −/+ | − | wt>M | +/− | + | −/+ | − | Napsin A, PIK3CA mutation | |
p53 M corresponds to intense and diffuse positivity in ≥60% of cells or complete negativity; p53 wt is the presence of rare cells weakly positive or positivity in <60% of cells.
AIS, endocervical adenocarcinoma in situ, of usual type; CCC, clear cell carcinoma; EAC, endocervical adenocarcinoma; EMC, endometrioid carcinoma; HPV+, human papilloma virus infection in situ hybridisation; M, mutant pattern; MMMT, malignant mixed Müllerian tumour; MMR, DNA mismatch repair genes; UC, undifferentiated carcinoma; USC, uterine serous carcinoma; wt, wild-type pattern.